Google
CARM — CARISMA THERAPEUTICS INC. (Healthcare >> Biotechnology)
CARM FAQ
What is CARM's ROE?
CARISMA THERAPEUTICS INC. reports a Return on Equity (ROE) of -927.57%.
What is CARM's dividend yield?
CARISMA THERAPEUTICS INC. offers a dividend yield of 0.00%.
What is CARM's Deepscope Quality Score?
Deepscope rates CARM's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CARM?
Deepscope's AI Timing Score for CARM is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CARM belong to?
CARISMA THERAPEUTICS INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.00
Price
0
(0%)
Day Change
|
|
|---|
CARM, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 63 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | N/A |
| PBV / Sector |
N/A / 4.48
|
| Earning Per Share | 0.19 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
172.597430000000
|
| Average 1W Daily Value |
2.053800000000
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
58% |
| Return to Investors |
|
37% |
| Registration Details |
| Analyze Date | 2026-06-04 09:23:27 |
| Symbol | CARM |
| Name | CARISMA THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 41.85 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | N/A / 8,483.11 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3675 Market Street, Philadelphia, PA, United States, 19104
Phone: 267 491 6422
Website: https://www.carismatx.com
Sector: Healthcare >> Biotechnology
Description: Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
